Adverse EventsDue to gynecological events observed at the 80 mg dose, the trial was amended to compare 40 mg Z-endoxifen + OFS to exemestane + OFS, using 4-week Ki-67 reduction as the primary endpoint.
CompetitionThe metastatic breast cancer development landscape is competitive, with several late clinical stage second generation oral SERDs in development.
Treatment CompetitionAnalyst believes that the oral SERD space in 2L+ patients has become increasingly competitive, though to date, Phase 3 trials have only indicated a benefit in ESR1 mutant patients.